No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRIX240719C2500
- 9.70
- 0.000.00%
15min DelayTrading Apr 22 14:34 ET
0.00High0.00Low
0.00Open9.70Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover0.00%IV-40.76%PremiumJul 19, 2024Expiry Date18.10Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.13Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 23.99% RBC Capital $23 → $26 Maintains Outperform 06/18/2024 23.99% HC Wainwright & Co. $19 → $
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $26
RBC Capital analyst Gregory Renza maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $23 to $26.According to TipRanks data, the analyst has a success rate of
Express News | Nurix Therapeutics Inc : RBC Raises Target Price to $26 From $23
Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)
Comments
$Nurix Therapeutics(NRIX.US$ Chif Lao BUYERS Sell now +💰💰💰💰💰💰💰💰💰🤗🤗🤗
$Nurix Therapeutics(NRIX.US$ Nurix Therapeutics Inc - Commenced an Underwritten Public Offering of $125 Mln of Its Common Stock
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Read more